Donepezil and memantine for moderate-to-severe Alzheimer's disease

<h4>Background</h4> <p>Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer’s disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.</p> <h4>Method...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Howard, R, McShane, R, Lindesay, J, Ritchie, C, Baldwin, A, Barber, R, Burns, A, Dening, T, Findlay, D, Holmes, C, Hughes, A, Jacoby, R, Jones, R, McKeith, I, Macharouthu, A, O'Brien, J, Passmore, P, Sheehan, B, Juszczak, E, Katona, C, Hills, R, Knapp, M, Ballard, C, Brown, R, Banerjee, S, Onions, C, Griffin, M, Adams, J, Gray, R, Johnson, T, Bentham, P, Phillips, P
Natura:	Journal article
Pubblicazione:	Massachusetts Medical Society 2012

Donepezil and memantine for moderate-to-severe Alzheimer's disease

Documenti analoghi